Cited by 420Computational Drug Discovery MethodsCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record, with a small difference in title or year; 10 of the 10 references it cites were found in a registry or an index.

Pharmacogenomic agreement between two cancer cell line data sets

Open access

The Cancer Cell Line Encyclopedia Consortium, The Genomics of Drug Sensitivity in Cancer Consortium·2015·Nature

DOI 10.1038/nature15736PMC PMC6343827

Open this paper in CoChat — free account

Abstract

Large cancer cell line collections broadly capture the genomic diversity of human cancers and provide valuable insight into anti-cancer drug response. Here we show substantial agreement and biological consilience between drug sensitivity measurements and their associated genomic predictors from two publicly available large-scale pharmacogenomics resources: The Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer databases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature15736

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citation
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2820 · Cited by 600
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J. M., Frommolt, P., Peifer, M., Li, D., Ullrich, R. T., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Advances in the preclinical testing of cancer therapeutic hypotheses
Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165
Comparison and validation of genomic predictors for anticancer drug sensitivity
Papillon‐Cavanagh, S., Jay, N. D., El-Hachem, N., Olsen, C., Bontempi, G., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001442 · Cited by 65

Show all 10 references

Sorted by citations

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931
Self-citation
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens
Repana, D., Nulsen, J., Dreßler, L., Bortolomeazzi, M., Venkata, S. K., Tourna, A., Yakovleva, A., Palmieri, T., & Ciccarelli, F. D. (2019) · Genome biology · doi:10.1186/s13059-018-1612-0 · Cited by 690
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458
Self-citation
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Reproducible pharmacogenomic profiling of cancer cell line panels
Haverty, P. M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R. M., Martin, S. E., Settleman, J., Yauch, R. L., et al. (2016) · Nature · doi:10.1038/nature17987 · Cited by 279
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13805-y · Cited by 254
Deep learning for drug response prediction in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz171 · Cited by 243
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens
Larsson, P., Engqvist, H., Biermann, J., Rönnerman, E. W., Forssell-Aronsson, E. B., Kovács, A., Karlsson, P., Helou, K., & Parris, T. Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-62848-5 · Cited by 239
Predicting drug response of tumors from integrated genomic profiles by deep neural networks
Chiu, Y., Chen, H.-I. H., Zhang, T., Zhang, S., Gorthi, A., Wang, L., Huang, Y., & Chen, Y. (2019) · BMC Medical Genomics · doi:10.1186/s12920-018-0460-9 · Cited by 232
Genomic evolution of cancer models: perils and opportunities
Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 234
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays
Li, J., Zhao, W., Akbani, R., Liu, W., Ju, Z., Ling, S., Vellano, C. P., Roebuck, P. L., Yu, Q., Eterovic, A. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.005 · Cited by 206
CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics
Luna, A., Elloumi, F., Varma, S., Wang, Y., Rajapakse, V. N., Aladjem, M. I., Robert, J., Sander, C., Pommier, Y. G., & Reinhold, W. C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa968 · Cited by 212
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 207
Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics
Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D., & Lu, X. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0378 · Cited by 195
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network
Liu, P., Li, H., Li, S., & Leung, K. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2910-6 · Cited by 189
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors
Lim, K. S., Li, H., Roberts, E. A., Gaudiano, E. F., Clairmont, C. S., Sambel, L. A., Ponnienselvan, K., Liu, J., Yang, C., Kozono, D., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.045 · Cited by 174
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris, I. S., Endress, J. E., Coloff, J. L., Selfors, L. M., McBrayer, S. K., Rosenbluth, J. M., Takahashi, N., Dhakal, S., Koduri, V., Oser, M. G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.020 · Cited by 171
Computational models for predicting drug responses in cancer research
Azuaje, F. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw065 · Cited by 59
Genome‐wide cooperation of EMT transcription factor ZEB1 with YAP and AP‐1 in breast cancer
Feldker, N., Ferrazzi, F., Schuhwerk, H., Widholz, S. A., Guenther, K., Frisch, I., Jakob, K., Kleemann, J., Riegel, D., Bönisch, U., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103209 · Cited by 171
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155
Machine learning in the prediction of cancer therapy
Rafique, R., Islam, S. M. R., & Kazi, J. U. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.003 · Cited by 156
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · iScience · doi:10.1016/j.isci.2018.11.029 · Cited by 158
Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data
Sidorov, P., Naulaerts, S., Ariey-Bonnet, J., Pasquier, E., & Ballester, P. J. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00509 · Cited by 158
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Liberio, M. D. S., Walther, T., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93801 · Cited by 151
Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers
Schick, S., Rendeiro, A. F., Runggatscher, K., Ringler, A., Boidol, B., Hinkel, M., Májek, P., Vulliard, L., Penz, T., Parapatics, K., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0477-9 · Cited by 147
Bioinformatics Approaches for Anti-cancer Drug Discovery
Li, K., Du, Y., Li, L., & Wei, D. (2019) · Current Drug Targets · doi:10.2174/1389450120666190923162203 · Cited by 145
Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics
Koromina, M., Pandi, M.-T., & Patrinos, G. P. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0151 · Cited by 140
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studiesPreprint
Geeleher, P., Zhang, Z., Wang, F., Gruener, R. F., Nath, A., Morrison, G., Bhutra, S., Grossman, R. L., & Huang, R. S. (2017) · Genome Research · doi:10.1101/gr.221077.117 · Cited by 142
An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression
Liu, C., Dong, W. G., Xiang, J., Ren, F., Huang, L., Lang, J., Tian, G., Li, Y., & Yang, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.003 · Cited by 138
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Lochmann, T. L., Floros, K. V., Naseri, M., Powell, K. M., Cook, W., March, R. J., Stein, G. T., Greninger, P., Maves, Y. K., Saunders, L. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1606 · Cited by 134
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Niepel, M., Hafner, M., Mills, C. E., Subramanian, K., Williams, E. H., Chung, M., Gaudio, B., Barrette, A. M., Stern, A. D., Hu, B., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.06.005 · Cited by 133
A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs
Girardi, E., César‐Razquin, A., Lindinger, S., Παπακώστας, Κ., Konecka, J., Hemmerich, J., Kickinger, S., Kartnig, F., Gürtl, B., Klavins, K., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0483-3 · Cited by 141
Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches
Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0049-y · Cited by 146
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining
Vougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 129
DeepTTA: a transformer-based model for predicting cancer drug response
Jiang, L., Jiang, C., Yu, X., Fu, R., Jin, S., & Liu, X. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac100 · Cited by 128
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125
Predictive approaches for drug combination discovery in cancer
Tonekaboni, S. A. M., Ghoraie, L. S., Manem, V. S., & Haibe‐Kains, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 118
Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limited conditions
Skinner, O. S., Blanco-Fernández, J., Goodman, R. P., Kawakami, A., Shen, H., Kemény, L. V., Joesch-Cohen, L. M., Rees, M. G., Roth, J. A., Fisher, D. E., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00774-2 · Cited by 120
An expanded landscape of human long noncoding RNA
Jiang, S., Cheng, S., Ren, L., Wang, Q., Kang, Y.-J., Ding, Y., Hou, M. L., Yang, X., Lin, Y., Liang, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz621 · Cited by 116
Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers
Wooten, D. J., Groves, S. M., Tyson, D. R., Liu, Q., Lim, J. S., Albert, R., Lopez, C. F., Sage, J., & Quaranta, V. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007343 · Cited by 118
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Libério, M. S., Walther, T., et al. (2017) · Kölner Universitäts PublikationsServer (Universität zu Köln) · doi:10.17863/cam.20903 · Cited by 111
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J. G., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2018) · Nature · doi:10.1038/s41586-018-0722-x · Cited by 109
Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling
Niepel, M., Hafner, M. A., Duan, Q., Wang, Z., Paull, E., Chung, M., Lü, X., Stuart, J. M., Golub, T. R., Subramanian, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01383-w · Cited by 93
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
Liu, J., Kong, X., Huang, T., Wang, R., Li, W., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02048 · Cited by 93
Paralog buffering contributes to the variable essentiality of genes in cancer cell lines
De Kegel, B., & Ryan, C. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008466 · Cited by 92
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 98
Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer
Xu, S., Zhan, M., Jiang, C., He, M. Y., Yang, L., Shen, H., Huang, S., Huang, X., Lin, R., Shi, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13420-x · Cited by 91
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Carugo, A., Minelli, R., Sapio, L., Soeung, M., Carbone, F., Robinson, F. S., Tepper, J., Chen, Z., Lovisa, S., Svelto, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.006 · Cited by 94
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
Cai, M., Dunn, C. E., Chen, W., Kochupurakkal, B. S., Nguyen, H. Q., Moreau, L. A., Shapiro, G. I., Parmar, K., Kozono, D., & D’Andrea, A. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.052 · Cited by 91
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Narayan, R. S., Molenaar, P., Teng, J., Cornelissen, F. M. G., Roelofs, I., de Menezes, R. X., Dik, R., Lagerweij, T., Broersma, Y., Petersen, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16735-2 · Cited by 89
Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics
Hafner, M. A., Niepel, M., & Sorger, P. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3882 · Cited by 83
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
Dammert, M. A., Brägelmann, J., Olsen, R. R., Böhm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11371-x · Cited by 82
CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
Szlachta, K. A., Kuscu, C., Tufan, T., Adair, S. J., Shang, S., Michaels, A. D., Mullen, M. G., Fischer, N. L., Yang, J., Liu, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06676-2 · Cited by 83
DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride
Liu, L., Xiong, D., Lin, P., Yang, H., Dang, Y., & Chen, G. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4531 · Cited by 80
Meta-GDBP: a high-level stacked regression model to improve anticancer drug response prediction
Su, R., Liu, X., Xiao, G., & Wei, L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz022 · Cited by 78
Mutational signatures are markers of drug sensitivity of cancer cells
Levatić, J., Salvadores, M., Fuster‐Tormo, F., & Supek, F. (2022) · Nature Communications · doi:10.1038/s41467-022-30582-3 · Cited by 79
Revisiting inconsistency in large pharmacogenomic studies
Safikhani, Z., Freeman, M., Smirnov, P., El-Hachem, N., She, A., Quevedo, R., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L. M., et al. (2016) · F1000Research · doi:10.12688/f1000research.9611.3 · Cited by 106
Deep learning of pharmacogenomics resources: moving towards precision oncology
Chiu, Y., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz144 · Cited by 80
Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer
Chang, A., Liu, L., Ashby, J. M., Wu, D., Chen, Y., O’Neill, S. S., HUANG, S. H., Wang, J., Wang, G., Cheng, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0688 · Cited by 77
Olfactory receptor gene abundance in invasive breast carcinoma
Masjedi, S., Zwiebel, L. J., & Giorgio, T. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-50085-4 · Cited by 76
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway
Chang, W., Chang, Y., Yang, Y., Lin, S.-K., Chang, P. M., & Hsiao, M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1256-2 · Cited by 74
Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs
Ren, X., Xie, X., Chen, B., Liu, L., Jiang, C., & Qian, Q. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02026 · Cited by 77
O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy
Lu, Q., Zhang, X., Liang, T., & Bai, X. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00544-y · Cited by 71
Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns
Salvadores, M., Fuster‐Tormo, F., & Supek, F. (2020) · Science Advances · doi:10.1126/sciadv.aba1862 · Cited by 70
A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
Li, Z., Chen, S., Feng, W., Luo, Y., Lai, H., Li, Q., Xiu, B., Li, Y., Li, Y., Huang, S., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103074 · Cited by 69
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Srour, N., Villarreal, O. D., Hardikar, S., Yu, Z., Preston, S. E. J., Miller, W. H., Szewczyk, M. M., Baršytė-Lovejoy, D., Xu, H., Chen, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110582 · Cited by 70
Signatures of cell death and proliferation in perturbation transcriptomics data—from confounding factor to effective prediction
Szalai, B., Subramanian, V., Holland, C. H., Alföldi, R., Puskás, L. G., & Sáez-Rodríguez, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz805 · Cited by 68
An overview of machine learning methods for monotherapy drug response prediction
Firoozbakht, F., Yousefi, B., & Schwikowski, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab408 · Cited by 70
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Zhou, S., Hawley, J. R., Soares, F., Grillo, G., Teng, M., Tonekaboni, S. A. M., Hua, J. T., Kron, K. J., Mazrooei, P., Ahmed, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14318-9 · Cited by 69
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., Alexe, G., Schauer, N. J., Liu, X., Bird, G. H., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171066 · Cited by 69
Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models
Sharifi-Noghabi, H., Jahangiri, S., Smirnov, P., Hon, C. S.-Y., Mammoliti, A., Nair, S. K., Mer, A. S., Ester, M., & Haibe‐Kains, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab294 · Cited by 66
Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments
Li, X., Li, J., Wu, P., Zhou, L., Lü, B., Ying, K., Chen, E., Lü, Y., & Liu, P. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1494677 · Cited by 65
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Sperling, A. S., Burgess, M. W., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M. M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 65
CENPE promotes lung adenocarcinoma proliferation and is directly regulated by FOXM1
Shan, L., Zhao, M., Lu, Y., Ning, H., Ouyang, C., Song, Y., Chai, W., & Shi, X. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4805 · Cited by 62
Comprehensive characterization of the rRNA metabolism-related genes in human cancer
Cui, K., Liu, C., Li, X., Zhang, Q., & Li, Y. (2019) · Oncogene · doi:10.1038/s41388-019-1026-9 · Cited by 63
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Safikhani, Z., Smirnov, P., Thu, K. L., Silvester, J., El-Hachem, N., Quevedo, R., Lupien, M., Mak, T. W., Cescon, D. W., & Haibe‐Kains, B. (2017) · Nature Communications · doi:10.1038/s41467-017-01153-8 · Cited by 60
Assessment of modelling strategies for drug response prediction in cell lines and xenografts
Kurilov, R., Haibe‐Kains, B., & Brors, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59656-2 · Cited by 62
The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy
Guan, Y., Chen, X., Wu, M., Zhu, W., Arslan, A., Takeda, S., Nguyen, M. H., Majeti, R., Thomas, D., Zheng, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.007 · Cited by 62
Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque
Fernández-Torras, A., Duran-Frigola, M., Bertoni, M., Locatelli, M., & Aloy, P. (2022) · Nature Communications · doi:10.1038/s41467-022-33026-0 · Cited by 59
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Mer, A. S., Ba-Alawi, W., Smirnov, P., Wang, Y. X., Brew, B., Ortmann, J., Tsao, M., Cescon, D. W., Goldenberg, A., & Haibe‐Kains, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0349 · Cited by 57
AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG/miR-22-3p
Chou, J., Kaller, M., Jaeckel, S., Rokavec, M., & Hermeking, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01581-1 · Cited by 58
Drug discovery and mechanism prediction with explainable graph neural networks
Wang, C., Kumar, G. A., & Rajapakse, J. C. (2025) · Scientific Reports · doi:10.1038/s41598-024-83090-3 · Cited by 67
Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model
Dong, W. G., Liu, C., Zheng, X., & Li, Y. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2608-9 · Cited by 56
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor
Roux, B., Vaganay, C., Vargas, J. D., Alexe, G., Benaksas, C., Pardieu, B., Fenouille, N., Ellegast, J. M., Małolepsza, E., Ling, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg1168 · Cited by 63
Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies
Pozdeyev, N. V., Yoo, M., Mackie, R., Schweppe, R. E., Tan, A. C., & Haugen, B. R. (2016) · Oncotarget · doi:10.18632/oncotarget.10010 · Cited by 55
Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1)
Koumantou, D., Barnea, E., Martín‐Esteban, A., Maben, Z., Papakyriakou, A., Mpakali, A., Kokkala, P., Pratsinis, H., Georgiadis, D., Stern, L. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02358-0 · Cited by 52
Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma
Hong, W., Zhang, Y., Wang, S., Zheng, D.-X., Hsu, S.-J., Zhou, J., Fan, J., Zeng, Z., Wang, N., Ding, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216594 · Cited by 54
A p62-dependent rheostat dictates micronuclei catastrophe and chromosome rearrangements
Martin, S., Scorzoni, S., Cordone, S., Mazzagatti, A., Beznoussenko, G. V., Gunn, A., Bona, M. D., Eliezer, Y., Leor, G., Ben-Yishay, T., et al. (2024) · Science · doi:10.1126/science.adj7446 · Cited by 56
Feature selection strategies for drug sensitivity prediction
Koras, K., Juraeva, D., Kreis, J., Mazur, J., Staub, E., & Szczurek, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-65927-9 · Cited by 55
In silico drug repositioning: from large-scale transcriptome data to therapeutics
Kwon, O., Kim, W., Cha, H., & Lee, H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01176-3 · Cited by 55
OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Cabrera‐Andrade, A., Barigye, S. J., Munteanu, C. R., González‐Díaz, H., Pazos, A., Pérez‐Castillo, Y., & Tejera, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-62279-2 · Cited by 55
Trypsin‐Instructed Self‐Assembly on Endoplasmic Reticulum for Selectively Inhibiting Cancer Cells
Kim, B. J., Fang, Y., He, H., & Xu, B. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000416 · Cited by 52

Authors: The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2015-11-16
Volume: 528
Issue: 7580
Pages: 84-87
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature15736
PMC: PMC6343827
OpenAlex: W2318806991
Cited by: 418
References: 10
Citations by year: 2026: 17 · 2025: 26 · 2024: 33 · 2023: 37 · 2022: 49 · 2021: 47 · 2020: 38 · 2019: 78 · 2018: 36 · 2017: 37 · 2016: 19
FWCI: 31.30
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: Wellcome Trust (086357, 102696STRATTON, 102696)
Cancer Research UK (A16629)
National Institutes of Health (5u54hg006097-03)
National Human Genome Research Institute (1U54HG006097-01, U54-HG006097)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: cancer cell lines, drug sensitivity, pharmacogenomics, GDSC, data concordance, anticancer drug response, drug library
MeSH terms: Humans, Neoplasms, Pharmacogenetics, Reproducibility of Results, Databases, Factual, Inhibitory Concentration 50, Cell Line, Tumor, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacogenomic agreement between two cancer cell line data sets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks